Marché mondial des déficits en hormone de croissance chez les enfants – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et taille du marché du déficit en hormone de croissance pédiatrique

L’augmentation de la prévalence des tumeurs de l’hypophyse et l’augmentation des dépenses de santé sont les principaux facteurs influençant le taux de croissance du marché. En outre, les progrès de la technologie médicale, l’augmentation du financement gouvernemental et les initiatives croissantes des organisations publiques et privées pour sensibiliser aux maladies oculaires sont les facteurs qui élargiront le marché du déficit en hormone de croissance pédiatrique. D’autres facteurs tels que l’augmentation du nombre de troubles endocriniens et l’augmentation du nombre de cas associés à une petite taille auront un impact positif sur le taux de croissance du marché. En outre, un nombre croissant de campagnes et de programmes de diagnostic pédiatrique dans les pays sous-développés entraînera l’expansion du marché du déficit en hormone de croissance pédiatrique.

Data Bridge Market Research analyse que le marché mondial du déficit en hormone de croissance pédiatrique, qui était de 3,45 milliards USD en 2023, devrait atteindre 13,87 milliards USD d'ici 2031 et devrait connaître un TCAC de 19,00 % au cours de la période de prévision. Les « tests sanguins » dominent le segment du diagnostic du marché en raison de la demande croissante de tests sanguins pour le diagnostic de l'hormone de croissance. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du déficit en hormone de croissance pédiatrique

Définition du marché

L'hormone de croissance est une hormone nécessaire à la croissance et au développement normaux. Elle est produite par l'hypophyse, une glande liée à l'hypothalamus et située près de la base du cerveau. L'hormone de croissance est une hormone qui est délivrée dans tout le corps par la circulation sanguine pour contribuer à diverses activités, dont la plus importante est la croissance, en particulier chez les enfants. Si l'hypophyse ou l'hypothalamus sont détruits, la quantité d'hormone de croissance produite est réduite (on parle alors de carence), ce qui entraîne un ralentissement de la croissance et une réduction de la taille de l'enfant affecté.

Dynamique du marché mondial du déficit en hormone de croissance pédiatrique

Conducteurs

• Incidence croissante du déficit en hormone de croissance chez les enfants

La sensibilisation croissante et l’amélioration des capacités de diagnostic contribuent à l’identification d’un plus grand nombre de cas de déficit en hormone de croissance chez l’enfant. En conséquence, le nombre de patients augmente, ce qui accroît la demande de thérapies à base d’hormone de croissance.

• Progrès en biotechnologie et en technologie de l'ADN recombinant

Les innovations en biotechnologie, notamment dans le développement d'hormones de croissance recombinantes, ont permis de proposer des options de traitement plus sûres et plus efficaces pour le déficit en hormone de croissance chez l'enfant. Ces avancées améliorent les perspectives globales du marché et augmentent l'accessibilité des thérapies avancées.

• Importance croissante accordée au diagnostic et au traitement précoces

On accorde de plus en plus d'importance au diagnostic et à l'intervention précoces pour les problèmes de santé pédiatriques, notamment le déficit en hormone de croissance. Une identification précoce permet un traitement rapide, ce qui peut améliorer les résultats et minimiser l'impact de la maladie sur la croissance et le développement de l'enfant.

• Des investissements en hausse pour les établissements de santé

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players about funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Strategic Collaborations and Partnerships

Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can lead to the development of innovative treatments, research initiatives, and improved diagnostic tools for pediatric growth hormone deficiency. Strategic partnerships can enhance the overall market ecosystem.

• Focus on Personalized Medicine

The trend toward personalized medicine opens opportunities for tailoring growth hormone therapies based on individual patient characteristics, genetic factors, and treatment responses. Precision medicine approaches may lead to more effective and targeted treatments, minimizing adverse effects and optimizing outcomes for pediatric patients.

Restraints

• High Cost of Treatment

Growth hormone therapies can be expensive, requiring a long-term commitment for effective treatment. The high cost of these therapies may pose a significant financial burden on families and healthcare systems, limiting accessibility for some patients.

• Adverse Effects and Safety Concerns

Some pediatric growth hormone therapies may be associated with side effects, and long-term safety concerns may influence treatment decisions. Safety considerations and potential adverse effects could impact patient compliance and contribute to hesitancy among healthcare providers and parents.

Challenges

• Diagnostic Complexity and Delayed Identification

The complexity of diagnosing pediatric growth hormone deficiency, which often requires specialized testing and careful evaluation, can lead to delays in identification. Limited routine screening may contribute to missed opportunities for early intervention and treatment.

• Limited Treatment Options for Certain Causes

Growth hormone deficiency can have various underlying causes, and treatment options may be limited or less effective in cases where the deficiency is associated with certain genetic or congenital conditions. Developing targeted therapies for specific causes presents a challenge.

This pediatric growth hormone deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pediatric growth hormone deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In February 2021, Pfizer Inc. initiated a Phase III clinical trial to evaluate the efficacy and safety of somatropin in a cohort of Japanese participants with Prader-Willi Syndrome (PWS)
• In October 2020, Erasmus Medical Center, in collaboration with Pfizer, Foundation for Prader-Willi Research, and Prader-Willi Fonds, initiated a Phase III clinical trial to assess the effect of growth hormone treatment (Genotropin) on physical and psychosocial health in adults of 30 years or older with Prader-Willi syndrome

Global Pediatric Growth Hormone Deficiency Market Scope

The pediatric growth hormone deficiency market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acquired
• Congenital
• Idiopathic

Treatment                                                                     

• Growth Hormone Shots
• Others

Diagnosis                                                                     

• Blood tests
• X-Ray
• CT Scan
• MRI
• GH Stimulation Test
• Others

Symptoms                                                                     

• Younger-Looking Face
• Delayed Puberty
• A chubby Body Build
• Impaired Hair Growth
• Others

Dosage

• Injection
• Others

Route of administration

• Subcutaneous
• Others

End user

• Clinic
• Hospital
• Others

Global Pediatric Growth Hormone Deficiency Market Regional Analysis/Insights

The pediatric growth hormone deficiency market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, and rest of Middle East and Africa.

North America is expected to dominate the market due to the presence of major key players, high disposable income, and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to show the fastest growth during the forecast period due to the increasing research and development activities, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The pediatric growth hormone deficiency market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for pediatric growth hormone deficiency market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the pediatric growth hormone deficiency market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Pediatric Growth Hormone Deficiency Market Share Analysis

The pediatric growth hormone deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pediatric growth hormone deficiency market.

Some of the major players operating in the pediatric growth hormone deficiency market are:

• Merck KGaA (Germany)
• Novo Nordisk A/S (Denmark)
• Genentech, Inc. (U.S.)
• Ferring B.V. (Switzerland)
• Eli Lilly and Company (U.S.)
• Pfizer Inc. (États-Unis)
• Novartis SA (Suisse)
• Biopartners GmbH (Suisse)
• F. Hoffmann-La Roche SA (Suisse)
• AnkeBio Co., Ltd. (Chine)
• GeneScience Pharmaceuticals Co., Ltd. (Chine)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Ipsen Pharma (France)
• LG Chem (Corée du Sud)

SKU-67399